C-Ray Therapeutics Secures Over $100 Million in A+ Round Financing
C-Ray Therapeutics (Chengdu) Co., Ltd., an innovative enterprise in the field of radioactive medicines, has...
Finance
Impact Therapeutics Secures $34.5 Million in Series D++ Financing for Senaparib Commercialization
China-based biopharmaceutical company Impact Therapeutics has reportedly secured RMB 250 million (USD 34.5 million) in...
PegBio Files for IPO on Hong Kong Stock Exchange
PegBio Co., Ltd., a specialist in endocrine metabolism based in Suzhou, has taken a significant...
Cullgen and Pulmatrix Merge to Form Nasdaq-Listed Protein Degradation Company
Cullgen Inc., a clinical-stage biopharmaceutical company with operations in China, the US, and Japan, is...
Sihuan Pharmaceutical Plans IPO for Xuanzhu Biopharm on Hong Kong Stock Exchange
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced a renewed attempt to spin...
Triton Partners Mulls Acquisition of Germany’s Evotec SE, Shares Soar 22%
Private equity firm Triton Partners is reportedly contemplating the acquisition of Germany-based Evotec SE (NASDAQ:...
Leman Biotech Secures Over USD 13.9 Million in Series A Financing for Next-Gen Cancer Immunotherapies
China-based Leman Biotech Co., Ltd. has reportedly completed the first closing of its Series A...
Jiangsu Kanion Pharmaceutical to Acquire Xintrum Pharmaceuticals for RMB 270 Million
Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557), a China-based pharmaceutical company, has announced its intention...
Nuwacell Biotechnologies Secures RMB150 Million in Series B Financing for iPSC Therapies
Nuwacell Biotechnologies Co., Ltd., a specialist in induced pluripotent stem cell (iPSC) technology based in...
Northeast Pharmaceutical to Acquire Majority Stake in Dingcheng Peptide Source for RMB 186.8 Million
China-based Northeast Pharmaceutical Co., Ltd (SHE: 000597) has announced its intention to acquire a 70%...
Neurodawn Pharmaceutical Secures Hundreds of Millions in Series C Financing
Nanjing-based central nervous system (CNS) drug developer, Neurodawn Pharmaceutical Co., Ltd, has announced the successful...
Innovent Biologics Halts Subscription Agreement with Lostrancos Ventures
China-based Innovent Biologics, Inc. (HKG: 1801) has announced the decision not to proceed with a...
Innovent’s Fortvita Stake Sale Sparks Controversy, Shares Plummet Nearly 13%
Innovent Biologics, Inc. (HKG: 1801), headquartered in China, has announced a subscription agreement in which...
TheDerma’s Series A+ Round to Fund R&D and Commercialization of AhR Targeted Drugs
TheDerma, a Shanghai-based pharmaceutical company, has announced the completion of a nearly CNY 100 million...
Beijing Biostar Technologies Goes Public in Hong Kong to Fund Cancer Drug Development
Beijing Biostar Technologies Ltd (HKG: 2563), a leading synthetic biology-driven anti-tumor drug specialist based in...
Macrolux Raises Over RMB 100 Million in Series B Financing
Macrolux, a leading medical technology company specializing in disposable endoscopes, has announced the completion of...
Otsuka Holdings Weighs Sale of Stake in Medical Device Maker MicroPort Scientific
Otsuka Holdings Co., a Japanese pharmaceutical and healthcare company, is reportedly considering the sale of...
Stem-Cell Startup Xellsmart Secures Over RMB 100 Million in Series B1 Financing for Neurological Therapies
Xellsmart, a stem-cell startup headquartered in Suzhou, has reportedly secured over RMB 100 million (USD...
Beijing Biostar Pharmaceuticals Set to Go Public on HKEX with Focus on Oncology Innovation
On October 18, 2024, the Hong Kong Stock Exchange announced that Beijing Biostar Pharmaceuticals Co.,...
LaNova Medicines Secures RMB 300 Million in Series C1 Financing to Advance Cancer Therapy Pipeline
LaNova Medicines Ltd, a Shanghai-based developer of cancer therapies, has announced the successful completion of...